PlainRecalls
FDA Drug Moderate Class II Terminated

Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL USA 33314, USA, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054 USA; NDC 58544-692-30.

Reported: August 10, 2022 Initiated: July 21, 2022 #D-1303-2022

Product Description

Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL USA 33314, USA, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054 USA; NDC 58544-692-30.

Reason for Recall

Failed Dissolution Specifications: below specification limits for dissolution.

Details

Units Affected
5677 bottles
Distribution
Nationwide in the USA and Puerto Rico
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL USA 33314, USA, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054 USA; NDC 58544-692-30.. Recalled by Teva Pharmaceuticals USA Inc. Units affected: 5677 bottles.
Why was this product recalled?
Failed Dissolution Specifications: below specification limits for dissolution.
Which agency issued this recall?
This recall was issued by the FDA Drug on August 10, 2022. Severity: Moderate. Recall number: D-1303-2022.